Activity OverviewThe ACR Convergence Replay includes six popular video lectures from scientific sessions at ACR Convergence 2024, plus a Q&A session for each. The lectures encompass a variety of topics, including systemic sclerosis, rheumatoid arthritis-related interstitial lung disease, juvenile dermatomyositis, and the use of AI documentation in rheumatology. The activity includes the following sessions: Optimizing the Management of Skin Disease in Systemic Sclerosis: Using Clinical Features and Novel Disease Activity Measures to Guide Treatment DecisionsAre We Putting the CAR-T Before the Horse?Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient PhenotypingAI: The Next Breakthrough in Documentation for RheumatologyAnti-MDA5 Juvenile Dermatomyositis: Clinical Presentation and TreatmentYear in Review Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. ACR/ARP Member: $299 ACR/ARP Potential Member: $399Target AudienceRheumatologists, internists, primary care providers, physician assistants, residents, fellows in training, advanced practice nurses, students, rheumatology interprofessionals who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.Learning ObjectivesUpon completion of this activity, participants should be able to: Analyze and explain recent scientific and clinical advancements in understanding the pathogenesis of rheumatic diseases Evaluate and demonstrate proficiency in diagnosing and managing a range of rheumatic diseases and conditions Apply evidence-based strategies to effectively manage emerging challenges in rheumatic conditionsCE/MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA Designation Statement The American College of Rheumatology designates this Enduring Material for a maximum of 8.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Participants can claim up to 1.25 AMA PRA Category 1 Credit(s)™ for completing the pre-and post-assessments, and up to 7.25 AMA PRA Category 1 Credit(s)™ for attending the ACR Convergence Replay 2024. CME credit must be claimed by April 3, 2028, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. Nature of Financial Relationships All individuals that participate in this activity and were able to change or influence the content of the activity have disclosed to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. ACR Convergence Replay 2024 Financial Relationship DisclosuresAcknowledgment of Commercial Support  No commercial support was provided for this activity. Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewRheum2Learn 2.0 is case-based fundamental clinical rheumatology education for residents. Each interactive activity includes three patient cases that focus on the care and assessment of individuals with rheumatologic diseases. The included activities use interactive patient cases to simulate clinical scenarios commonly encountered in primary care, inpatient, and critical care settings. Learners are guided to recognize disease patterns, build differential diagnoses, select appropriate tests, and develop treatment strategies in collaboration with rheumatology specialists. Key topics span rheumatoid arthritis, lupus, crystalline arthritis, osteoarthritis, myopathies, systemic sclerosis, pediatric rheumatology, infectious arthritis, osteoporosis, and vasculitis. See below for a complete list of the 15 included activities.Rheum2Learn SeriesThis activity is part of a series. See the other activities in the series below.Rheum2Learn 2.0: Crystalline ArthritisRheum2Learn 2.0: Infectious ArthritisRheum2Learn 2.0: Inflammatory MyopathiesRheum2Learn 2.0: Musculoskeletal DisordersRheum2Learn 2.0: Musculoskeletal ExaminationRheum2Learn 2.0: OsteoporosisRheum2Learn 2.0: OsteoarthritisRheum2Learn 2.0: Pediatric RheumatologyRheum2Learn 2.0: Rheumatic Manifestations of Systemic DiseaseRheum2Learn 2.0: Rheumatoid ArthritisRheum2Learn 2.0: Sjögren’s DiseaseRheum2Learn 2.0: SpondyloarthritisRheum2Learn 2.0: Systemic Lupus ErythematosusRheum2Learn 2.0: Systemic SclerosisRheum2Learn 2.0: Systemic VasculitisRegistration is complimentary.Target AudienceResidents in training who may provide care for patients with rheumatic diagnoses in primary care, inpatient, critical care, and other clinical contexts.The activity may also be of interest to medical students, fellows in training, advanced practice providers, practicing physicians, and other health care professionals who seek to strengthen their clinical knowledge of rheumatic diseases.Learning ObjectivesUpon completion of this activity, participants should be able to:Recognize disease patterns using clinical data and patient history.Formulate a comprehensive differential diagnosis based on disease patterns and diagnostic clues.Select appropriate diagnostic tests and labs to narrow down the diagnosis.Develop treatment strategies in collaboration with rheumatology specialists.See individual activities (linked above) for activity-specific learning objectives. CE & MOC InformationThis activity is not eligible for CME/MOC.Acknowledgement of Commercial SupportRheum2Learn 2.0: Inflammatory Myopathies, Rheum2Learn 2.0: Systemic Lupus Erythematosus, Rheum2Learn 2.0: Pediatric Rheumatology, Rheum2Learn 2.0: Rheumatic Manifestations of Systemic Disease, Rheum2Learn 2.0: Sjögren’s DiseaseThese projects were supported by grant number 1 NU58DP006908-01-00 – Component A: Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology.  The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. In this activity, you will learn how to accurately diagnose, administer appropriate treatments, and establish care plans for patients with inflammatory myopathy, Sjögren’s disease, and scleroderma.Advanced Rheumatology Course SeriesThis activity is part of a series. See the other activities in the series below.Advanced Rheumatology Course: All ActivitiesARC01: Musculoskeletal Structure And Function And Inflammation And ImmunityARC02: Framework for Clinical Decision Making in RheumatologyARC03: Laboratory Evaluation of Rheumatic DiseaseARC04: Imaging of ArthritisARC05: Coding and Practice IssuesARC06: Therapeutic Interventions And ResourcesARC07: OsteoarthritisARC08: RA and Seronegative Inflammatory ArthropathiesARC09: Systemic Lupus ErythematosusARC010: Systemic Inflammatory Conditions: Inflammatory MyopathyARC11: Vasculitis, Arteritis and PMRARC12: Crystal-Induced ArthropathiesARC13: Pain SyndromesARC14: SpondyloarthritisARC15: Infection-Related ArthritisARC16: Osteoporosis And Other Metabolic Bone DisordersARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)ARC19: Pediatric Noninflammatory Musculoskeletal PainRegistration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.Target AudienceAdvanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.Learning ObjectivesUpon completion of this activity, participants should be able to: Scleroderma:Define sclerodermaDescribe the epidemiology and pathogenesis of sclerodermaDescribe the clinical features, differential diagnosis, clinical course, and prognosis of sclerodermaDiscuss the treatment of sclerodermaDiscuss future directions in assessing and managing immune-mediated disorders (scleroderma and idiopathic inflammatory myositis)Idiopathic Inflammatory Myositis (IIM)Define idiopathic inflammatory myositis, or IIMDescribe the epidemiology and pathogenesis of IIMDescribe the clinical features, differential diagnosis, clinical course, and prognosis of IIMDiscuss the treatment of IIMDiscuss future directions in assessing and managing immune-mediated disorders (scleroderma and idiopathic inflammatory myositis)Sjögren’s syndrome (SS)Define Sjögren’s syndrome (SS)Describe the epidemiology and pathogenesis of SSDescribe the clinical features, differential diagnosis, clinical course, and prognosis of SSDiscuss the treatment of SSDiscuss future directions in assessing and managing SSCE & MOC InformationACCME Accreditation StatementThe American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.CME credit must be claimed by August 14, 2026, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.Authors/PlannersJason Kolfenbach, MD: ChemoCentryx5 Tara Skorupa, MD: No relevant financial relationships to discloseEditors and ReviewersZsuzsanna McMahon – No relevant financial relationships to discloseMarcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2Julie Lahti – No relevant financial relationships to discloseAcknowledgement of Commercial SupportThe project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.